Tuesday, September 7, 2021 Daily Archives

Bioprocess 101 – Cell Culture Media Analysis

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Graziella Piras, Segment Marketing Director, Bioprocessing, Marketing, 908 Devices Cell culture media analysis is a critical piece of the bioprocessing puzzle. From starting material and throughout the growth cycle, cell culture media analysis gives you a clearer, fuller picture of how amino acids, vitamins, and biogenic amines impact cell health and productivity. This Ask the Expert session will outline two of the key applications of cell media analysis in the production of biologics: media quality control (QC)…

BioLife bolsters CGT portfolio through Sexton acquisition

BioLife will boost its cell and gene therapy offerings by acquiring Cook Regentec spin out firm, Sexton Biotechnologies. BioLife Solutions has purchased the remaining shares of Sexton, a firm that provides manufacturing services for the cell and gene therapy industry, in a deal valued at $24 million. Sexton has two product lines; processing and handling solutions and cell performance supplements, which it uses to support cell and gene therapy production. Its portfolio includes human platelet lysate (HPL) media, a bio-defined…

CDMOs snapping up plants – a microtrend in the CGT space?

Various cell therapy firms have sold their inhouse facilities, but is this a trend in industry or just coincidence? While manufacturing outsourcing is a staple part of the biopharma world, over the past few years many advanced therapy developers – including Pfizer, Astellas, Allogene and Regenxbio – have lauded the decision to invest inhouse. Many have cited inhouse capabilities as necessary to keep full manufacturing control over complex processes, while others cite the lack of third-party capacity and long booking…